These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 14735723)

  • 1. Advances in the pathogenesis of liver cirrhosis.
    Castilla Cortázar A
    Rev Med Univ Navarra; 1993; 38(2):51-7. PubMed ID: 14735723
    [No Abstract]   [Full Text] [Related]  

  • 2. Over expression of transforming growth factor-alpha and epidermal growth factor receptor in human hepatic cirrhosis tissues.
    Qiao Q; Zhang J; Wang W; Li Q
    Hepatogastroenterology; 2008; 55(81):169-72. PubMed ID: 18507100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease.
    Adams LA; Angulo P
    Clin Liver Dis; 2007 Feb; 11(1):25-35, viii. PubMed ID: 17544970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pathogenesis and classification of liver cirrhosis].
    Popper H
    Med Klin; 1969 Jan; 64(3):89-92. PubMed ID: 5764142
    [No Abstract]   [Full Text] [Related]  

  • 5. [Transforming growth factor beta 1 and liver cirrhosis].
    Gao CF
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(15):1074-7. PubMed ID: 16029559
    [No Abstract]   [Full Text] [Related]  

  • 6. Matrix metalloproteinase, hepatocyte growth factor, and tissue inhibitor of matrix metalloproteinase during human liver regeneration.
    Fuke H; Saitou Y; Nakano T; Uemoto S; Shiraki K
    Liver Int; 2006 Apr; 26(3):380-1. PubMed ID: 16584402
    [No Abstract]   [Full Text] [Related]  

  • 7. Serum and urinary fucose concentrations in hepatitis B-related cirrhosis and acute liver diseases.
    Sathish Kumar N; Eapen CE; Jeyamani R; Balasubramanian KA
    Clin Chim Acta; 2004 Apr; 342(1-2):233-5. PubMed ID: 15026286
    [No Abstract]   [Full Text] [Related]  

  • 8. Towards the non-invasive diagnosis of cirrhosis: the nuts-cirrhosis connection.
    Bosch J
    J Hepatol; 2009 Jan; 50(1):4-6. PubMed ID: 19019481
    [No Abstract]   [Full Text] [Related]  

  • 9. [Electron microscopic findings in liver cirrhosis].
    Cossel L
    Dtsch Z Verdau Stoffwechselkr; 1967 Dec; 27(5):157-66. PubMed ID: 5595737
    [No Abstract]   [Full Text] [Related]  

  • 10. Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease.
    McClain CJ; Song Z; Barve SS; Hill DB; Deaciuc I
    Am J Physiol Gastrointest Liver Physiol; 2004 Sep; 287(3):G497-502. PubMed ID: 15331349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cirrhosis reversal: a duel between dogma and myth.
    Desmet VJ; Roskams T
    J Hepatol; 2004 May; 40(5):860-7. PubMed ID: 15094237
    [No Abstract]   [Full Text] [Related]  

  • 12. Relationship between circulating levels of tumour necrosis factor-alpha and Child-Pugh scores in liver cirrhosis.
    Odeh M
    Int J Clin Pract; 2007 Mar; 61(3):519; author reply 520. PubMed ID: 17313624
    [No Abstract]   [Full Text] [Related]  

  • 13. Peripheral blood serum markers for apoptosis and liver fibrosis: are they trustworthy indicators of liver realness?
    Torre F; Bellis L; Delfino A; Pelli N; Contini P; Basso M; Puoti C; Picciotto A
    Dig Liver Dis; 2008 Jun; 40(6):441-5. PubMed ID: 18294939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive clinical assessment improves the accuracy of predicting cirrhosis in chronic hepatitis C.
    Gordon A; Bailey MJ; Gibson PR; Roberts SK
    J Gastroenterol Hepatol; 2005 Jun; 20(6):825-32. PubMed ID: 15946128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Growth factors in assessing hepatic fibrosis in patients with chronic hepatitis C].
    Ivkova AN; Il'chenko LIu; Kushlinskiĭ NE; Petrenko NV; Storozhakov GI
    Eksp Klin Gastroenterol; 2008; (5):42-6. PubMed ID: 19145916
    [No Abstract]   [Full Text] [Related]  

  • 16. Reticulated platelets as a marker of megakaryopoiesis in liver cirrhosis; relation to thrombopoietin and hepatocyte growth factor serum concentration.
    Panasiuk A; Prokopowicz D; Zak J; Panasiuk B
    Hepatogastroenterology; 2004; 51(58):1124-8. PubMed ID: 15239259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanding the applicability of noninvasive fibrosis markers in HIV/HCV co-infected patients.
    Schiavon LL; Filho RJ; Narciso JL; Sampaio JP; Lanzoni VP; Ferraz ML; Silva AE
    Hepatology; 2007 Jan; 45(1):257-8. PubMed ID: 17187416
    [No Abstract]   [Full Text] [Related]  

  • 18. External validation of FibroIndex.
    Halfon P; Penaranda G; Renou C; Bourliere M
    Hepatology; 2007 Jul; 46(1):280-1; author reply 281-2. PubMed ID: 17596884
    [No Abstract]   [Full Text] [Related]  

  • 19. Can serum markers be used to reliably detect liver fibrosis?
    Afdhal N
    Nat Clin Pract Gastroenterol Hepatol; 2005 Mar; 2(3):132-3. PubMed ID: 16265151
    [No Abstract]   [Full Text] [Related]  

  • 20. [Increased CA-125 also in liver cirrhosis].
    Siboni A; Kassem V; Vemmelund S; Petersen PL; Jelert H
    Ugeskr Laeger; 2005 Jan; 167(2):189-90; author reply 190. PubMed ID: 15697137
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.